About Douglas Bryant
Douglas Bryant is a director of Nuclein. He was president and chief executive officer of QuidelOrtho, a diagnostics company in San Diego, until February 2024. He had led it, then called Quidel, since March 2009. In April 2024 he joined the board of Vital Biosciences, a Toronto company developing a device that runs routine lab tests on a small blood sample.
Earlier he was executive vice president and chief operating officer of Luminex Corporation. From 1983 to 2007 he held worldwide commercial operations jobs at Abbott Laboratories. They included vice president of Abbott Vascular for Asia and Japan and vice president of global commercial operations at Abbott Molecular and Abbott Diagnostics. He was also Abbott's managing director for the United Kingdom and Ireland. He holds a bachelor's degree in economics from the University of California, Davis.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Douglas Bryant in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Douglas Bryant works with at each company, as listed on that company's latest Form D.
Douglas Bryant in the News
Sources
- SECNuclein, LLC Form D/A, filed Oct 27, 2026
- SEC filingQuidelOrtho proxy statement (April 5, 2023): Douglas C. Bryant biography
- SEC filingQuidelOrtho Form 8-K (filed February 21, 2024): President and CEO through February 21, 2024
- Press releaseVital Biosciences release on Business Wire (April 9, 2024), read through a Financial Post copy
- Company siteCompany page on vitalbio.com (October 2025): lists Doug Bryant, former CEO of QuidelOrtho, among its strategic advisors